Back to Archived News
Vicor Technologies Receives Allowance of United States Patent Application Related to Its State Dependent Drug Development Platform
Tuesday, May 04, 2010
Boca Raton, FL -- David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced the Company received a Notice of Allowance for its U.S. Patent Application No. 10/359,363 for a method of treating ischemia through administration of a biologic identified through Vicor's state dependent drug discovery platform. Upon issuance, this patent will provide Vicor with patent protection for methods of using a peptide to treat infarctions, such as cardiac or cerebral infarctions.
Vicor has filed several patent applications associated with the development of peptides and proteins derived from "state-dependent" physiologies to advance the treatment of a wide variety of human conditions. Vicor's state dependent drug discovery platform identifies peptides and proteins derived from variations in physiologies of one state of an animal as compared with a different state of the animal. This platform may be used to advance the treatment of an array of human conditions, including stroke (cerebral ischemia), cardiac ischemia, kidney failure, hypertension, obesity, cancer, and organ transplant/preservation, by reducing the cost, time, and risk associated with bringing related pharmaceuticals to market. Vicor has twelve international patents issued or allowed related to this platform, including Europe, Eurasia, Australia, and South Africa.
"This is the patent we've been eagerly awaiting, as it is the first U.S. patent we've received related to a molecule identified using our drug discovery platform. While the studies that gave rise to the patent have only been performed in animals on a pre-clinical basis, the issuance of a patent is exciting news. This patent provides us protection for our advancements in this arena and also paves the way for us to aggressively pursue additional patents related to our drug discovery platform in the United States. With this protection, we can evaluate the most appropriate strategy to generate shareholder value for this platform," stated Mr. Fater.
About Vicor Technologies, Inc.
Vicor Technologies is focused on commercializing innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i® nonlinear algorithm and software to stratify patients at risk of sudden cardiac death and trauma victims in need of lifesaving intervention. Vicor also has filed several patents associated with the development of peptides and proteins derived from "state-dependent" physiologies to advance the treatment of a wide variety of human conditions.
The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability. Physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in multiple clinical trials, identifies patients at risk of sudden cardiac death.
Vicor anticipates additional applications employing the PD2i® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.
The appearance of name-brand institutions or products in this media release does not constitute endorsement by the U.S. Army Medical Research and Materiel Command, the Department of the Army, Department of Defense or the U.S. Government of the information, products or services contained therein.
Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to obtain FDA approval of our products, including approval of the PD2i VS™ (Vital Sign) for military and civilian applications and the PD2i CA™(Cardiac Analyzer); our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor's Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.
Back to Archived News